Baseline and follow-up data of patients with lupus nephritis in the IgG4-negative group and IgG4-positive group
| IgG4-negative group, n=59 | IgG4-positive group, n=30 | P value | |
| Age (years) | 33.56±12.91 | 33.30±12.83 | 0.93 |
| Gender (male/female) | 11/48 | 5/25 | 0.82 |
| Positive anti-dsDNA antibody, n (%) | 31 (54.4) | 12 (40.0) | 0.20 |
| SLEDAI score | 13.78±6.67 | 12.00±4.45 | 0.19 |
| IgG (mg/dL) | 1203.60±678.27 | 1257.97±646.85 | 0.72 |
| IgM (mg/dL) | 111.33±94.72 | 112.62±71.09 | 0.95 |
| IgA (mg/dL) | 266.64±125.09 | 253.07±120.22 | 0.63 |
| C3 (mg/dL) | 49.90±25.20 | 53.59±37.36 | 0.63 |
| C4 (mg/dL) | 9.29±9.09 | 11.21±10.53 | 0.38 |
| WCC (×109/L) | 5.78±2.83 | 4.83±3.61 | 0.18 |
| HB (g/dL(g/L)) | 101.44±21.98 | 102.93±24.57 | 0.77 |
| PLT (×109/L) | 176.71±72.46 | 171.53±65.19 | 0.74 |
| Urine protein (g/g) | 3.23 (1.60, 4.75) | 3.15 (1.84, 4.96) | 0.90 |
| Haematuria | 116.00 (26.20, 405.20) | 95.30 (39.55, 148.23) | 0.47 |
| Serum albumin (g/L) | 28.29±6.31 | 25.06±8.61 | 0.05 |
| Serum creatinine (μmol/L) | 79.00 (59.00, 166.00) | 74.00 (59.50, 99.75) | 0.34 |
| eGFR (mL/min/1.73 m2) | 80.42±42.13 | 89.99±35.19 | 0.26 |
| Pathological classification, n (%) | 0.03 | ||
| Ⅱ | 2 (3.4) | 0 (0) | |
| Ⅲ/Ⅳ | 36 (61.0) | 12 (40.0) | |
| Ⅴ | 9 (15.3) | 12 (40.0) | |
| Ⅲ/Ⅳ+Ⅴ | 12 (20.3) | 6 (20.0) | |
| Crescent, n (%) | 26 (44.1) | 8 (26.7) | 0.11 |
| Glomerular sclerosis, n (%) | 33 (55.9) | 12 (40.0) | 0.16 |
| PLA2R staining, n (%) | 11 (18.6) | 13 (43.3) | 0.01 |
| C3 deposition, n (%) | 43 (72.9) | 14 (46.7) | 0.02 |
| C4 deposition, n (%) | 24 (40.7) | 12 (40) | 0.95 |
| C1q deposition, n (%) | 36 (61.0) | 20 (66.7) | 0.60 |
| IgM deposition, n (%) | 42 (71.2) | 20 (66.7) | 0.66 |
| IgA deposition, n (%) | 40 (67.8) | 19 (63.3) | 0.67 |
| IgG deposition, n (%) | 39 (66.1) | 28 (93.3) | 0.01 |
| IgG1 deposition | 59 (64.4) | 29 (96.7) | 0.01 |
| IgG2 deposition | 35 (59.3) | 23 (65.2) | 0.10 |
| IgG3 deposition | 29 (49.2) | 20 (66.7) | 0.12 |
| Multisite deposits under EM (≥2 sites), n (%) | 56 (100) | 30 (100) | |
| Subendothelial deposit | 30 (53.6) | 15 (50.0) | 0.75 |
| Immunosuppressive treatment, n (%) | 0.83 | ||
| Steroids+cyclophosphamide | 11 (18.6) | 5 (16.7) | |
| Steroids+mycophenolate mofetil | 18 (30.5) | 7 (23.3) | |
| Steroids+ciclosporin/tacrolimus | 15 (25.4) | 8 (26.7) | |
| Steroids+others | 15 (25.4) | 10 (33.3) | |
| Follow-up (months) | 30.78±11.92 | 34.00±11.91 | 0.23 |
| Treatment response, n (%) | 0.01 | ||
| CR | 42 (71.1) | 17 (56.6) | |
| PR | 4 (6.8) | 9 (30.0) | |
| No response | 13 (23.0) | 4 (13.3) | |
| Renal outcome event, n (%) | 12 (20.3) | 1 (3.3) | 0.03 |
CR, complete response; dsDNA, double-stranded DNA; eGFR, estimated glomerular filtration rate; EM, electron microscopy; HB, haemoglobin; PLA2R, phospholipase A2 receptor; PLT, platelet; PR, partial response; SLEDAI, Systemic Lupus Erythematous Disease Activity Index; WCC, white cell count.